Marked Chart Marked Chart Closed · opens Mon 9:30 AM ET

The Marked Chart Wire · Business

Regeneron

Regeneron revenue growth driven by Dupixent profit share despite Eylea decline

Regeneron revenue continues to grow at a solid pace even as sales of its Eylea drug fall. The company's profit share from Dupixent is emerging as a key driver of its financial performance.

REGN-1.7%

Illustration for the Business desk

More Business news

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.